Why You Might Want to Cancel That Restaurant Reservation
The cost of dining out rose 3 percent in May year-over-year, while the amount paid to eat at home inched up just 0.6 percent. The growing disparity in prices could prompt consumers to abandon restaurants for home-cooked meals, according to a report today by Bloomberg.
“Eating in hasn’t been this attractive compared to dining out since 2010,” Bloomberg reports. That’s good news for consumers worried about their budgets, but could be a problem for restaurants’ bottom lines.
So far, consumers aren’t making the shift. This spring, spending at restaurants and bars totaled more than sales at grocery stores for the first time.
Related: The 11 Worst Fast Food Restaurants in America
Part of the reason consumers are sticking with restaurants could be that wages are starting to slowly increase, so consumers have a little more money to spend on meals.
They may also be dining out because it’s often an easier option. Shopping and preparing meals takes time – time that people simply don’t have these days. A quarter of employees say that they are working after the standard work day has ended, and about 40 percent work at least one weekend a month, according to Staples Advantage. That leaves little time for food prep.
Supermarkets have responded to the time-pressed consumer by increasingly offering prepared meals that require little more than reheating at home. The prices for such meals tend to be higher than the cost of their ingredients but less than the price of eating out or ordering in.
Chart of the Day: Boosting Corporate Tax Revenues
The leading candidates for the Democratic presidential nomination have all proposed increasing taxes on corporations, including raising income tax rates to levels ranging from 25% to 35%, up from the current 21% imposed by the Republican tax cuts in 2017. With Bernie Sanders leading the way at $3.9 trillion, here’s how much revenue the higher proposed corporate taxes, along with additional proposed surtaxes and reduced tax breaks, would generate over a decade, according to calculations by the right-leaning Tax Foundation, highlighted Wednesday by Bloomberg News.
Chart of the Day: Discretionary Spending Droops
The federal government’s total non-defense discretionary spending – which covers everything from education and national parks to veterans’ medical care and low-income housing assistance – equals 3.2% of GDP in 2020, near historic lows going back to 1962, according to an analysis this week from the Center on Budget and Policy Priorities.
Chart of the Week: Trump Adds $4.7 Trillion in Debt
The Committee for a Responsible Federal Budget estimated this week that President Trump has now signed legislation that will add a total of $4.7 trillion to the national debt between 2017 and 2029. Tax cuts and spending increases account for similar portions of the projected increase, though if the individual tax cuts in the 2017 Republican overhaul are extended beyond their current expiration date at the end of 2025, they would add another $1 trillion in debt through 2029.
Chart of the Day: The Long Decline in Interest Rates
Are interest rates destined to move higher, increasing the cost of private and public debt? While many experts believe that higher rates are all but inevitable, historian Paul Schmelzing argues that today’s low-interest environment is consistent with a long-term trend stretching back 600 years.
The chart “shows a clear historical downtrend, with rates falling about 1% every 60 years to near zero today,” says Bloomberg’s Aaron Brown. “Rates do tend to revert to a mean, but that mean seems to be declining.”
Chart of the Day: Drug Price Plans Compared
Lawmakers are considering three separate bills that are intended to reduce the cost of prescription drugs. Here’s an overview of the proposals, from a series of charts produced by the Kaiser Family Foundation this week. An interesting detail highlighted in another chart: 88% of voters – including 92% of Democrats and 85% of Republicans – want to give the government the power to negotiate prices with drug companies.
